<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4482190</article-id><article-id pub-id-type="pmid">26112005</article-id><article-id pub-id-type="publisher-id">1468</article-id><article-id pub-id-type="doi">10.1186/s12885-015-1468-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Mena<sup>calc</sup>, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Forse</surname><given-names>Catherine L.</given-names></name><address><email>catherine.forse@mail.utoronto.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Agarwal</surname><given-names>Seema</given-names></name><address><email>seema.agarwal@georgetown.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pinnaduwage</surname><given-names>Dushanthi</given-names></name><address><email>Pinnad@lunenfeld.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gertler</surname><given-names>Frank</given-names></name><address><email>fgertler@mit.edu</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Condeelis</surname><given-names>John S.</given-names></name><address><phone>718-678-1126</phone><email>John.Condeelis@einstein.yu.edu</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Juan</given-names></name><address><email>Juan.Lin@einstein.yu.edu</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Xiaonan</given-names></name><address><email>Xianonan.Xue@einstein.yu.edu</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Johung</surname><given-names>Kimberly</given-names></name><address><email>Kimberly.Johung@yale.edu</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Mulligan</surname><given-names>Anna Marie</given-names></name><address><email>AnnaMarie.Mulligan@uhn.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Rohan</surname><given-names>Thomas E.</given-names></name><address><email>Thomas.Rohan@einstein.yu.edu</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Bull</surname><given-names>Shelley B.</given-names></name><address><email>Bull@lunenfeld.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Andrulis</surname><given-names>Irene L.</given-names></name><address><phone>416-586-8256</phone><email>Andrulis@lunenfeld.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON Canada </aff><aff id="Aff2"><label>2</label>Department of Pathology, Yale University School of Medicine, New Haven, CT USA </aff><aff id="Aff3"><label>3</label>Department of Pathology, Georgetown University, Washington, DC USA </aff><aff id="Aff4"><label>4</label>Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON Canada </aff><aff id="Aff5"><label>5</label>Department of Biology and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Massachusetts, MA USA </aff><aff id="Aff6"><label>6</label>Department of Anatomy and Structural Biology, Gruss Lupper Biophotonics Center, Integrated Imaging Program, Albert Einstein College of Medicine, New York, NY USA </aff><aff id="Aff7"><label>7</label>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY USA </aff><aff id="Aff8"><label>8</label>Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT USA </aff><aff id="Aff9"><label>9</label>Laboratory Medicine Program, University Health Network, Toronto, ON Canada </aff><aff id="Aff10"><label>10</label>Dalla Lana School of Public Health, University of Toronto, Toronto, ON Canada </aff><aff id="Aff11"><label>11</label>Department of Molecular Genetics, University of Toronto, Toronto, ON Canada </aff><aff id="Aff12"><label>12</label>Department of Pathology &#x00026; Laboratory Medicine, Mount Sinai Hospital, Toronto, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>483</elocation-id><history><date date-type="received"><day>10</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Forse et al. 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Mena<sup>calc</sup> is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Mena<sup>calc</sup> and risk of death from breast cancer. Our goal was to determine if Mena<sup>calc</sup> could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer.</p></sec><sec><title>Methods</title><p>Analysis of the association of Mena<sup>calc</sup> with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Mena<sup>calc</sup> with risk of death after adjustment for HER2 status and clinicopathological tumor features.</p></sec><sec><title>Results</title><p>High Mena<sup>calc</sup> was associated with increased risk of death from any cause (<italic>P</italic>&#x02009;=&#x02009;0.0199, HR (CI)&#x02009;=&#x02009;2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Mena<sup>calc</sup> cohort which did not receive hormone or chemotherapy (n&#x02009;=&#x02009;142) (<italic>P</italic>&#x02009;=&#x02009;0.0052, HR (CI)&#x02009;=&#x02009;3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Mena<sup>calc</sup> in the HER2, basal and luminal molecular subtypes.</p></sec><sec><title>Conclusions</title><p>Mena<sup>calc</sup> may serve as an independent prognostic biomarker for the ANN breast cancer patient population.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12885-015-1468-6) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mena</kwd><kwd>Metastasis</kwd><kwd>Breast cancer</kwd><kwd>Axillary node negative</kwd><kwd>Prognostic marker</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>The majority of women diagnosed with axillary node-negative (ANN) breast cancer have a good prognosis; however, approximately 20&#x000a0;% of patients will experience a recurrence and die from systemic disease. Studies suggest that the risk of recurrence may depend on biologic subtype [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Gene expression and immunohistochemical marker profiling have been used to divide breast cancers into subtypes (i.e., luminal, basal-like, human epidermal growth factor 2 (HER-2) positive) which differ in terms of prevalence, recurrence risk, and sensitivity to chemotherapy [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. The identification of prognostic markers for ANN breast cancer in order to detect patients who would receive the most benefit from adjuvant systemic therapy would improve survival and decrease the number of patients exposed to unnecessary treatment.</p><p>Mena is a pro-motility protein that is a member of the Enabled (Ena)/vasodilator-stimulated phosphoprotein (VASP) family of actin polymerization regulators [<xref ref-type="bibr" rid="CR7">7</xref>]. It controls the geometry of assembling F-actin networks by antagonizing the activity of capping proteins at elongating actin filaments [<xref ref-type="bibr" rid="CR8">8</xref>]. The protein is overexpressed in primary and metastatic breast cancers [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], is particularly over-expressed in migratory and disseminating subpopulations of tumor cells <italic>in vivo</italic> [<xref ref-type="bibr" rid="CR11">11</xref>], and has been shown to have an important role in breast cancer metastasis in both <italic>in vitro</italic> and <italic>in vivo</italic> experimental models [<xref ref-type="bibr" rid="CR12">12</xref>]. It is an essential member of the Invasion Signature, a collection of transiently expressed proteins that control chemotactic and migratory behavior in primary rat, mouse and human mammary tumors [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. In mouse models of breast cancer, forced overexpression of Mena increased lung metastases [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>], while Mena deficiency decreased tumor burden by delaying tumor invasion, intravasation and dissemination to the lungs [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Studies of breast cancer cell migration and dissemination during metastasis at single cell resolution using multiphoton imaging in both mouse and human mammary tumors have led to the identification of microanatomic sites called Tumor MicroEnvironment of Metastasis (TMEM) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. TMEM are sites of localized vascular permeability induced by macrophage vascular endothelial growth factor (VEGF) release where tumor cells intravasate [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>Tumor cell migration toward TMEM <italic>in vivo</italic> occurs in association with macrophages and involves epidermal growth factor (EGF)/colony stimulating factor 1 (CSF-1) paracrine signaling [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Studies of these migratory tumor cells led to the identification of the Invasion Signature which contains pathways up-regulated in gene expression and/or protein activity in tumor cells, with migration and TMEM assembly activity leading to transendothelial migration at TMEM and dissemination to distant sites [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. These pathways involve epithelial-to-mesenchymal transition-associated differential expression of Mena isoforms [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Mena is alternatively spliced into multiple isoforms with Mena<sup>INV</sup> and Mena11a being the best characterized in breast cancer [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Mena<sup>INV</sup>, an invasive isoform, is spontaneously over-expressed in the migratory and disseminating subpopulation of tumor cells in primary mammary tumors of rat, mouse and humans [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. It confers a potent pro-invasion, pro-metastatic phenotype when expressed in breast cancer cells by potentiating their chemotactic invasion/migration response to EGF and by promoting discohesive cell motility [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Mena11a, which contains a 21 amino acid exon insertion, is down-regulated in invasive breast tumor cells [<xref ref-type="bibr" rid="CR11">11</xref>] and is down-regulated when human mammary epithelial cells undergo epithelial-to-mesenchymal transition [<xref ref-type="bibr" rid="CR25">25</xref>]. Mena11a expression in breast cancer cells causes formation of a poorly metastatic tumor which does not respond to EGF signaling <italic>in vivo</italic> [<xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, tumor cells with elevated transendothelial migration activity, isolated from breast cancer patients by fine needle aspiration, have spontaneously elevated Mena<sup>INV</sup> and suppressed Mena 11a expression [<xref ref-type="bibr" rid="CR26">26</xref>]. In addition, patients with elevated Mena<sup>INV</sup> and decreased Mena 11a expression have greatly elevated TMEM counts [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>Mena has shown promise as a prognostic marker for breast cancer. Its expression as a component of TMEM is associated with an increased risk of distant metastases in breast cancer patients [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p>Mena expression in Mena<sup>calc</sup>, a multiplexed quantitative immunofluorescence-based method which takes into consideration the differential expression of Mena protein isoforms, is also associated with poor outcome [<xref ref-type="bibr" rid="CR29">29</xref>]. Mena<sup>calc</sup> involves subtracting the protein expression of the non-metastatic Mena11a isoform from total Mena expression in tumors to give an estimate of the invasive Mena isoforms. In two tumor cohorts unselected for nodal status, Mena<sup>calc</sup> was associated with decreased disease-specific survival independent of patient age, receptor status and tumor size [<xref ref-type="bibr" rid="CR29">29</xref>]. While Mena<sup>calc</sup> was prognostic for poor outcome in node-positive patients, its role as a prognostic marker for ANN patients was unclear.</p><p>In this report, we evaluate the prognostic value of Mena<sup>calc</sup> in a cohort of ANN patients. Our primary objective was to determine if there was an association between Mena<sup>calc</sup> and overall patient mortality. A secondary objective was to determine if there was an association between Mena<sup>calc</sup> and mortality within subgroups defined by (1) adjuvant treatment received, and (2) breast cancer molecular subtypes. These associations could help to identify patient populations more likely to benefit from Mena<sup>calc</sup> testing.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patient cohort and clinical follow-up</title><p>The characteristics of a prospectively ascertained consecutive series of 1561 ANN cases enrolled from eight Toronto hospitals between September 1987 and March 1993 and clinically followed for recurrence and death have been described previously [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In brief, all women who had ANN invasive breast cancer pathologically confirmed at the participating centers were potentially eligible. The pathology report was used to determine the initial eligibility (which required clear resection margins and at least four lymph nodes sampled), pathologic size of the invasive component (centrally reviewed at Mount Sinai Hospital, Toronto, ON, Canada), presence of vascular or lymphatic invasion by tumor cells, estrogen receptor (ER) status, progesterone receptor (PgR) status, nuclear grading, histologic grading, and histologic subtype of the invasive and intraductal components (if present). Imaging (bone scan and abdominal ultrasound or abdominal computed tomography scan) and chest x-ray were required for patients with T2 tumors. If the patient was eligible on the basis of pathology, staging and age (between 18 and 75&#x000a0;years inclusive), the surgeon invited the patient to participate and provided a signed consent form. Patients were excluded from recruitment into this ANN cohort if (1) No tumor specimen was provided for analysis, (2) no axillary dissection was performed as part of surgical management, (3) less than four lymph nodes were biopsied and analyzed, (4) pathology revealed that the patient was diagnosed with carcinoma-in-situ disease (i.e., no invasive component), (5) the patient had distant metastases at the time of diagnosis, (6) the patient had synchronous primary breast tumors, (7) the patient had a previous breast malignancy, and (8) the patient had a secondary malignancy other than non-melanoma of the skin and carcinoma-in-situ of the cervix. Charts were reviewed every 3&#x000a0;months in the first 2&#x000a0;years after diagnosis, every 6&#x000a0;months until 5&#x000a0;years after diagnosis, and annually thereafter. Patient status on July 10, 2002 was used to determine survival times and censoring status using clinical follow-up data.</p><p>Approval of the study protocol was obtained from the research ethics boards of Mount Sinai Hospital (#01-0313-U) and the University Health Network (#02-0881-C), Toronto. Written-informed consent was received from all study participants. In the preparation of this paper, we used the reporting recommendations for tumor marker prognostic studies (REMARK) to present our results [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec4"><title>TMA construction and IHC staining</title><p>Tissue microarrays (TMAs) were constructed from tumors of 888 women and biomarker status was determined as described below. Areas of invasive carcinoma were selected from a hematoxylin and eosin-stained section of each tumor and two 0.6-mm cores of tissue were taken from the corresponding areas of the paraffin block. The selected donor cores were embedded in a paraffin block and 4-&#x003bc;m sections were cut from this recipient block and used in series for immunohistochemical (IHC) staining. Microwave antigen retrieval was carried out in a Micromed T/T Mega Microwave Processing Lab Station (ESBE Scientific). Slides were pretreated at 115&#x000a0;&#x000b0;C for 12&#x000a0;minutes in TTMega Tris (pH&#x000a0;9.0) and incubated with antibodies to ER (clone 6&#x000a0;F11, 1:75 dilution, Vector, Burlington, ON, Canada), PgR (clone PgR1294, 1:1000 dilution, DAKO, Glostrup, Denmark), p53 (clone D.07, 1:400 dilution, ID Lab), or CK5 (clone XM26, 1:400 dilution, Vector, Burlington, ON, Canada). Alternatively, slides were pretreated with pepsin at 37&#x000a0;&#x000b0;C for 10&#x000a0;minutes and then incubated with antibodies to EGFR (clone 31G7, 1:25 dilution, Zymed, South San Francisco, CA, U.S.A.) or HER-2 (clone CB11/TAB250 (cocktail), 1:300 dilution, Novocastra, Newcastle upon Tyne, U.K. and Zymed, South San Francisco, CA, U.S.A.). Sections were developed with diaminobenzidine tetrahydrochloride and counterstained in Mayer&#x02019;s hematoxylin.</p></sec><sec id="Sec5"><title>Antibodies and multiplexed immunofluorescence staining for Mena</title><p>The TMAs were deparaffinized by melting at 60&#x000a0;&#x000b0;C in an oven equipped with a fan for 20&#x000a0;minutes followed by 2x xylene treatment for 20&#x000a0;minutes. Slides were then rehydrated and antigen retrieval was done in citrate buffer (pH&#x000a0;6.0) at 97&#x000a0;&#x000b0;C for 20&#x000a0;minutes in a PT module (Labvision, Kalamazoo, MI, U.S.A.). Endogenous peroxidase was blocked by using 0.3&#x000a0;% hydrogen peroxide in methanol followed by incubation of slides in a blocking buffer (0.3&#x000a0;% bovine serum albumin in TBST (0.1&#x000a0;mol/L of TRIS-buffered saline (pH&#x000a0;7.0) containing 0.05&#x000a0;% Tween-20)) for 30&#x000a0;minutes at room temperature. Slides were incubated with a cocktail of mouse anti-pan-Mena (1:1000 dilution, BD Biosciences, San Jose, CA, U.S.A., catalog number 610693) mixed with rabbit anti-Mena11a (1:500 dilution of 1&#x000a0;mg/ml stock, generated in the lab of FG) in the blocking buffer overnight at 4&#x000a0;&#x000b0;C. After washing away the primary antibodies, slides were incubated with secondary antibody (goat anti-rabbit conjugated to horseradish peroxidase, Jackson ImmunoResearch Laboratories Inc., West Grove, PA, U.S.A.) to target Mena11a for one hour. After washing, slides were incubated with biotinylated tyramide (Perkin Elmer, Waltham, MA, U.S.A.) diluted at 1:50 in amplification buffer for 10&#x000a0;minutes. After washing, peroxidase activity was quenched by 2x treatment with benzoic hydrazide (100&#x000a0;mM in PBS) with 50&#x000a0;mM hydrogen peroxide for seven minutes each. After washing, slides were incubated for an hour with goat anti-mouse envision (DAKO, Carpinteria, CA, U.S.A.) followed by treatment with a chicken anti-Pan cytokeratin (1:100 dilution, generated in house) for 2&#x000a0;hours at room temperature. Slides were washed and then incubated with goat anti-chicken conjugated to Alexa546 (Invitrogen, Grand Island, NY, U.S.A.) to visualize cytokeratin and streptavidin conjugated to CY7 (750&#x000a0;nm, Invitrogen, Grand Island, NY, U.S.A.) to visualize Mena11a for an hour. After washing, slides were treated with CY5 conjugated tyramide (1:50 dilution; Perkin Elmer, Waltham, MA, U.S.A.) in amplification buffer for 10&#x000a0;minutes to visualize pan-Mena. Slides were mounted with ProLong gold mixed with DAPI (Molecular Probes, Grand Island, NY, U.S.A.). Serial sections of the index array used for assay standardization [<xref ref-type="bibr" rid="CR33">33</xref>] were stained alongside each cohort to assess the assay reproducibility. An additional serial section of the index array was stained with each experiment with no primary antibodies as a negative control.</p><p>Of the 888 tumors submitted for Mena multiplex immunofluorescence staining, 403 had sufficient tumor material to permit reliable interpretation of pan-Mena and Mena11a.</p></sec><sec id="Sec6"><title>Automated quantitative analysis (AQUA) and calculation of Mena<sup>calc</sup></title><p>The automated quantitative analysis (AQUA) technology (HistoRx, Branford, CT, U.S.A.) allows quantitative measurement of biomolecules in subcellular compartments as described previously [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Briefly, a series of monochromatic images for each histospot was captured using a PM-2000 microscope (HistoRx, Branford, CT, U.S.A.) equipped with an automated stage. A binary &#x02018;tumor mask&#x02019; was created using cytokeratin staining of the histospot representing only epithelial cells and excluding stromal features. AQUA scores for both pan-Mena and Mena11a were calculated by dividing the signal intensity by the area of the specific compartment (in this case within the tumor mask area). Normalized AQUA scores for both targets (pan-Mena and Mena11a) were used to calculate the Mena<sup>calc</sup> fraction for each histospot by subtracting the z score of Mena11a from the z score of pan-Mena as described previously [<xref ref-type="bibr" rid="CR29">29</xref>]. At the end of this procedure, Mena<sup>calc</sup> was obtained for 403 tumors from the ANN cohort.</p></sec><sec id="Sec7"><title>Subgroup definitions</title><sec id="Sec8"><title>Treatment subgroups</title><p>The study group (n&#x02009;=&#x02009;403) was divided into 2 groups based on adjuvant treatment: those who received no systemic adjuvant treatment and those who received any systemic adjuvant treatment (hormonal and/or chemotherapy). The two groups were called untreated (n&#x02009;=&#x02009;142) and treated (n&#x02009;=&#x02009;261) respectively.</p></sec><sec id="Sec9"><title>Molecular subtypes</title><p>The tumors were divided into molecular subtypes using IHC-TMA markers described in previous publications [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. Tumors positive for HER2 protein overexpression, regardless of ER status, were assigned to the HER2 subtype. Tumors negative for HER2 and ER and positive for one or both of CK5 and EGFR were assigned to the basal subtype. Tumors negative for HER2 but positive for ER were assigned to the luminal subtype, regardless of CK5 status.</p></sec></sec><sec id="Sec10"><title>Statistical analysis</title><p>Pearson&#x02019;s correlation coefficient (<italic>R</italic>) was used to assess the reproducibility of the multiplexed assay between near-serial sections of the index assay as described previously [<xref ref-type="bibr" rid="CR29">29</xref>]. Pan-Mena and Mena11a AQUA scores, and Mena<sup>calc</sup> values from two independent cores for each histospot were averaged and the averages were used for final analysis. Mena<sup>calc</sup> scores were categorized as scores that were at or above the median (Mena<sup>calc</sup> high) or below the median (Mena<sup>calc</sup> low). This median cutoff was selected because of the division noted in the Kaplan Meier (K-M) survival curves generated from quartile groups. The chi-square test or Fisher&#x02019;s exact test was used to analyze the Mena<sup>calc</sup> marker associations with clinical-pathological tumor variables. Analysis of the association of overall survival (OS) with marker status was performed using K-M survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Multivariate analyses by the Cox PH model were conducted to assess the contribution of Mena<sup>calc</sup>, in addition to HER2 status (using IHC data), hormone receptors (using IHC data) and other clinical-pathological tumor variables. Hazard ratios (HRs) and 95&#x000a0;% confidence intervals (CI) were also estimated, with Firth&#x02019;s bias corrected penalized Cox regression method [<xref ref-type="bibr" rid="CR39">39</xref>] applied for subgroup analyses with a small number of events. A test with a <italic>P</italic>-value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. All tests were two-sided. P-values were not adjusted for multiple testing. All statistical analyses were performed using SAS 9.1 software (SAS Institute, Inc.). Survival curves were plotted using R statistical software, version 2.15.0 (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link>).</p></sec></sec><sec id="Sec11" sec-type="results"><title>Results and discussion</title><sec id="Sec12"><title>Clinicopathological characteristics</title><p>The patient and tumor characteristics of the subgroup of 403 patients for which Mena<sup>calc</sup> was obtained and the remaining subset of the TMA cohort (n&#x02009;=&#x02009;888) are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Compared to the remaining cohort (n&#x02009;=&#x02009;483), patients included in the Mena<sup>calc</sup> analysis were of younger age, more likely to be pre-menopausal and more likely to have larger tumors.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Association between clinical markers and Mena<sup>calc</sup> expression availability in the TMA cohort (n&#x02009;=&#x02009;888)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Characteristic</th><th colspan="2">Mena<sup>calc</sup> score available</th><th colspan="2">Mena<sup>calc</sup> score unavailable</th><th><italic>P</italic>-value<sup>d</sup></th></tr></thead><tbody><tr><td colspan="2"/><td colspan="2">(<italic>n</italic>&#x02009;=&#x02009;403<sup>a</sup>)</td><td colspan="2">(<italic>n</italic>&#x02009;=&#x02009;483)</td><td/></tr><tr><td colspan="2"/><td>Number</td><td>%</td><td>Number</td><td>%</td><td/></tr><tr><td colspan="7">Menopausal status</td></tr><tr><td/><td>pre</td><td>151</td><td>37.5</td><td>141</td><td>29.2</td><td>0.0330</td></tr><tr><td/><td>peri</td><td>19</td><td>4.7</td><td>25</td><td>5.2</td><td/></tr><tr><td/><td>post</td><td>233</td><td>57.8</td><td>317</td><td>65.6</td><td/></tr><tr><td>Tumor Size</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>&#x0003c;0.5&#x000a0;cm</td><td>5</td><td>1.2</td><td>11</td><td>2.3</td><td>0.0198</td></tr><tr><td/><td>0.5 to&#x02009;&#x0003c;&#x02009;1.0&#x000a0;cm</td><td>41</td><td>10.2</td><td>81</td><td>16.8</td><td/></tr><tr><td/><td>1.0 to&#x02009;&#x0003c;&#x02009;2.0&#x000a0;cm</td><td>174</td><td>43.2</td><td>199</td><td>41.2</td><td/></tr><tr><td/><td>2 to 5&#x000a0;cm</td><td>164</td><td>40.7</td><td>179</td><td>37.0</td><td/></tr><tr><td/><td>&#x0003e;5&#x000a0;cm</td><td>19</td><td>4.7</td><td>13</td><td>2.7</td><td/></tr><tr><td colspan="7">Estrogen receptor</td></tr><tr><td/><td>Positive</td><td>239</td><td>59.3</td><td>307</td><td>63.6</td><td>0.2806</td></tr><tr><td/><td>Negative/Equivocal</td><td>104</td><td>25.8</td><td>103</td><td>21.3</td><td/></tr><tr><td/><td>ND<sup>b</sup></td><td>60</td><td>14.9</td><td>73</td><td>15.1</td><td/></tr><tr><td colspan="7">Progesterone receptor</td></tr><tr><td/><td>Positive</td><td>215</td><td>53.3</td><td>280</td><td>58.0</td><td>0.2699</td></tr><tr><td/><td>Negative/Equivocal</td><td>128</td><td>31.8</td><td>130</td><td>26.9</td><td/></tr><tr><td/><td>ND<sup>b</sup></td><td>60</td><td>14.9</td><td>73</td><td>15.1</td><td/></tr><tr><td colspan="7">Histological grade</td></tr><tr><td/><td>1<sup>c</sup></td><td>99</td><td>24.6</td><td>174</td><td>36.0</td><td>&#x0003c;0.0001</td></tr><tr><td/><td>2</td><td>147</td><td>36.4</td><td>152</td><td>31.5</td><td/></tr><tr><td/><td>3</td><td>132</td><td>32.8</td><td>100</td><td>20.7</td><td/></tr><tr><td/><td>ND<sup>b</sup></td><td>25</td><td>6.2</td><td>57</td><td>11.8</td><td/></tr><tr><td colspan="7">Adjuvant treatment</td></tr><tr><td/><td>Hormonal</td><td>169</td><td>41.9</td><td>205</td><td>42.4</td><td>0.0571</td></tr><tr><td/><td>Chemotherapy</td><td>78</td><td>19.4</td><td>64</td><td>13.3</td><td/></tr><tr><td/><td>Both</td><td>14</td><td>3.5</td><td>14</td><td>2.9</td><td/></tr><tr><td/><td>None</td><td>142</td><td>35.2</td><td>200</td><td>41.4</td><td/></tr><tr><td colspan="7">Lymphatic Invasion</td></tr><tr><td/><td>Yes</td><td>70</td><td>17.4</td><td>47</td><td>9.7</td><td>0.0008</td></tr><tr><td/><td>No</td><td>332</td><td>82.6</td><td>436</td><td>90.3</td><td/></tr><tr><td/><td>Missing</td><td>1<sup>e</sup></td><td/><td>0</td><td/><td/></tr><tr><td>Age group</td><td colspan="6"/></tr><tr><td/><td>&#x0003c;50&#x000a0;yrs</td><td>157</td><td>39.0</td><td>149</td><td>30.9</td><td>0.0115</td></tr><tr><td/><td>&#x02265;50&#x000a0;yrs</td><td>246</td><td>61.0</td><td>334</td><td>69.1</td><td/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>without patients with most baseline unavailable data</p><p><sup>b</sup>Unknown, not done or missing</p><p><sup>c</sup>Includes mucinous, lobular and tubular subtypes</p><p><sup>d</sup>Chi-square test</p><p>(<sup>e</sup>without missing category)</p></table-wrap-foot></table-wrap></p><p>The patient and tumor characteristics of the Mena<sup>calc</sup> high (at or above the median) and low (below the median) groups are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Tumors with high Mena<sup>calc</sup> values were more likely to be higher grade and to have lymphatic invasion. These patients were also more likely to have received hormonal therapy and/or chemotherapy. 58 deaths were observed during follow-up. Excluding deaths and a small number of drop-outs, minimum and median follow-up times were 56.1 and 96.5&#x000a0;months respectively. Of the 54 recurrences observed, 15 patients presented with bone metastases alone, 14 patients presented with chest wall or regional lymph node involvement (either axillary or supraclavicular), 8 patients presented with lung metastases alone, 2 patients presented with liver metastases alone, 1 patient presented with skin metastases alone and 1 patient presented with a solitary neck muscle deposit. 8 patients presented with bone and liver metastases and 3 patients presented with bone and lung metastases. 2 patients presented with widespread multi-organ involvement (bone, liver and lung). The average time to recurrence was 41.8&#x000a0;months (s.d.&#x02009;=&#x02009;23&#x000a0;months). A table outlining the average time and range of time to recurrence for each metastases subgroup is included as Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Association between clinical markers and Mena<sup>calc</sup> expression (n&#x02009;=&#x02009;403)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Characteristic</th><th colspan="2">Mena<sup>calc</sup> low</th><th colspan="2">Mena<sup>calc</sup> high</th><th rowspan="2"><italic>P</italic>-value<sup>c</sup></th></tr><tr><th/><th/><th colspan="2">(<italic>n</italic>&#x02009;=&#x02009;202)</th><th colspan="2">(<italic>n</italic>&#x02009;=&#x02009;201)</th></tr></thead><tbody><tr><td/><td/><td>Number</td><td>%</td><td>Number</td><td>%</td><td/></tr><tr><td>Death</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>Yes</td><td>22</td><td>10.9</td><td>36</td><td>17.9</td><td>0.0447</td></tr><tr><td/><td>No</td><td>180</td><td>89.1</td><td>165</td><td>82.1</td><td/></tr><tr><td colspan="2">Menopausal status</td><td/><td/><td/><td/><td/></tr><tr><td/><td>pre</td><td>72</td><td>35.6</td><td>79</td><td>39.3</td><td>0.6969</td></tr><tr><td/><td>peri</td><td>9</td><td>4.5</td><td>10</td><td>5.0</td><td/></tr><tr><td/><td>post</td><td>121</td><td>59.9</td><td>112</td><td>55.7</td><td/></tr><tr><td colspan="2">Tumor Size</td><td/><td/><td/><td/><td/></tr><tr><td/><td>&#x0003c;0.5&#x000a0;cm</td><td>2</td><td>1.0</td><td>3</td><td>1.5</td><td>0.8845</td></tr><tr><td/><td>0.5 to&#x02009;&#x0003c;&#x02009;1.0&#x000a0;cm</td><td>21</td><td>10.4</td><td>20</td><td>10.0</td><td/></tr><tr><td/><td>1.0 to&#x02009;&#x0003c;&#x02009;2.0&#x000a0;cm</td><td>91</td><td>45.0</td><td>83</td><td>41.2</td><td/></tr><tr><td/><td>2 to 5&#x000a0;cm</td><td>80</td><td>39.6</td><td>84</td><td>41.8</td><td/></tr><tr><td/><td>&#x0003e;5&#x000a0;cm</td><td>8</td><td>4.0</td><td>11</td><td>5.5</td><td/></tr><tr><td colspan="2">Estrogen receptor</td><td/><td/><td/><td/><td/></tr><tr><td/><td>Positive</td><td>124</td><td>61.4</td><td>115</td><td>57.2</td><td>0.3701</td></tr><tr><td/><td>Negative/Equivocal</td><td>46</td><td>22.8</td><td>58</td><td>28.9</td><td>0.1926<sup>d</sup></td></tr><tr><td/><td>ND<sup>a</sup></td><td>32</td><td>15.8</td><td>28</td><td>13.9</td><td/></tr><tr><td colspan="2">Progesterone receptor</td><td/><td/><td/><td/><td/></tr><tr><td/><td>Positive</td><td>112</td><td>55.5</td><td>103</td><td>51.3</td><td>0.4136</td></tr><tr><td/><td>Negative/Equivocal</td><td>58</td><td>28.7</td><td>70</td><td>34.8</td><td>0.2245<sup>d</sup></td></tr><tr><td/><td>ND<sup>a</sup></td><td>32</td><td>15.8</td><td>28</td><td>13.9</td><td/></tr><tr><td colspan="2">Histological grade</td><td/><td/><td/><td/><td/></tr><tr><td/><td>1<sup>b</sup></td><td>58</td><td>28.7</td><td>41</td><td>20.4</td><td>0.2389</td></tr><tr><td/><td>2</td><td>71</td><td>35.2</td><td>76</td><td>37.8</td><td/></tr><tr><td/><td>3</td><td>60</td><td>29.7</td><td>72</td><td>35.8</td><td/></tr><tr><td/><td>ND<sup>a</sup></td><td>13</td><td>6.4</td><td>12</td><td>6.0</td><td/></tr><tr><td colspan="2">Adjuvant treatment</td><td/><td/><td/><td/><td/></tr><tr><td/><td>Hormonal</td><td>76</td><td>37.6</td><td>93</td><td>46.3</td><td>0.0985</td></tr><tr><td/><td>Chemotherapy</td><td>37</td><td>18.3</td><td>41</td><td>20.4</td><td/></tr><tr><td/><td>Both</td><td>10</td><td>5.0</td><td>4</td><td>2.0</td><td/></tr><tr><td/><td>None</td><td>79</td><td>39.1</td><td>63</td><td>31.3</td><td/></tr><tr><td colspan="2">Lymphatic Invasion</td><td/><td/><td/><td/><td/></tr><tr><td/><td>Yes</td><td>27</td><td>13.4</td><td>43</td><td>21.5</td><td>0.0315</td></tr><tr><td/><td>No</td><td>175</td><td>86.6</td><td>157</td><td>78.5</td><td/></tr><tr><td/><td>Missing</td><td>0</td><td/><td>1</td><td/><td/></tr><tr><td>Age group</td><td/><td/><td/><td/><td/><td/></tr><tr><td/><td>&#x0003c;50&#x000a0;yrs</td><td>73</td><td>36.1</td><td>84</td><td>41.8</td><td>0.2447</td></tr><tr><td/><td>&#x02265;50&#x000a0;yrs</td><td>129</td><td>63.9</td><td>117</td><td>58.2</td><td/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Unknown, not done or missing</p><p><sup>b</sup>Includes mucinous, lobular and tubular subtypes</p><p><sup>c</sup>By Chi-square test (without Missing category)</p><p><sup>d</sup>Without ND group</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Association of Mena<sup>calc</sup> with patient survival</title><sec id="Sec14"><title>Full group (n&#x02009;=&#x02009;403)</title><p>Women in the Mena<sup>calc</sup> low group had significantly better overall survival compared to women in the Mena<sup>calc</sup> high group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>: K-M survival curves; Log-Rank <italic>P</italic>&#x02009;=&#x02009;0.0227). In univariate Cox regression analysis, when Mena<sup>calc</sup> status was considered alone, there was a 1.84-fold (CI&#x02009;=&#x02009;(1.08, 3.14), <italic>P</italic>&#x02009;=&#x02009;0.0248) higher risk of death in the Mena<sup>calc</sup> high group (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The magnitude and significance of the Mena<sup>calc</sup> high association with death persisted with adjustment for HER2 status, hormone receptor status and other clinicopathological tumor variables (HR&#x02009;=&#x02009;2.18, CI&#x02009;=&#x02009;(1.19, 4.00), <italic>P</italic>&#x02009;=&#x02009;0.0199) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Kaplan-Meier analysis of Mena<sup>calc</sup> in the ANN patient cohort (n&#x02009;=&#x02009;403, top left), in a subset of patients who received chemotherapy and/or hormone therapy (n&#x02009;=&#x02009;261, top right) and in a subset of the patient population that did not receive chemotherapy or hormone therapy (n&#x02009;=&#x02009;142, bottom left). Mena<sup>calc</sup> scores were categorized as Mena<sup>calc</sup> high if they were at or above the median and Mena<sup>calc</sup> low if they were below the median. In brackets is the total number of patients followed by the number of patient deaths for each group</p></caption><graphic xlink:href="12885_2015_1468_Fig1_HTML" id="d30e2436"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Results of Overall Survival Analysis by Cox Proportional Hazards Model for the full dataset</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Prognostic Factor</th><th colspan="2">Univariate (<italic>n</italic>&#x02009;=&#x02009;403)</th><th colspan="2">Multivariate (<italic>n</italic>&#x02009;=&#x02009;360<sup>c</sup>)</th></tr></thead><tbody><tr><td colspan="2"/><td>HR (95&#x000a0;% CI)</td><td>P-value</td><td>HR (95&#x000a0;% CI)</td><td><italic>P</italic>-value</td></tr><tr><td colspan="6">Mena<sup>calc</sup></td></tr><tr><td/><td>High vs. Low</td><td>1.84 (1.08, 3.14)</td><td>0.0248</td><td>2.18 (1.19, 4.00)</td><td>0.0199</td></tr><tr><td colspan="6">Her2<sup>a</sup></td></tr><tr><td/><td>Positive vs. Negative</td><td>1.71 (0.77, 3.79)</td><td>0.1855</td><td>1.43 (0.58, 3.53)</td><td>0.4341</td></tr><tr><td colspan="6">Tumor Size</td></tr><tr><td/><td>&#x02265;2&#x000a0;cm vs. &#x0003c;2&#x000a0;cm</td><td>1.40 (0.83, 2.35)</td><td>0.2024</td><td>1.45 (0.80, 2.66)</td><td>0.2234</td></tr><tr><td colspan="6">ER<sup>a</sup></td></tr><tr><td/><td>Negative vs. Positive</td><td>1.18 (0.65, 2.13)</td><td>0.5858</td><td>1.09 (0.57, 2.08)</td><td>0.7952</td></tr><tr><td colspan="6">PR<sup>a</sup></td></tr><tr><td/><td>Positive vs. Negative</td><td>2.36 (1.32, 4.25)</td><td>0.0040</td><td>NA<sup>b</sup></td><td>NA<sup>b</sup></td></tr><tr><td colspan="6">Histological grade</td></tr><tr><td/><td>Grade 2-3 vs. Grade 1</td><td>1.62 (0.82, 3.22)</td><td>0.1682</td><td>1.27 (0.59, 2.72)</td><td>0.5450</td></tr><tr><td/><td>ND vs. Grade 1</td><td>1.06 (0.33, 3.42)</td><td>0.9264</td><td>0.75 (0.22, 2.49)</td><td>0.6354</td></tr><tr><td colspan="6">Lymphatic invasion</td></tr><tr><td/><td>Present vs. Absent</td><td>1.78 (0.97, 3.26)</td><td>0.0614</td><td>1.67 (0.85, 3.30)</td><td>0.1359</td></tr><tr><td colspan="6">Treatment</td></tr><tr><td/><td>Yes vs. No</td><td>0.60 (0.35, 1.00)</td><td>0.0514</td><td>0.54 (0.29, 0.99)</td><td>0.0454</td></tr><tr><td colspan="6">Age, years</td></tr><tr><td/><td>&#x02265;50 vs. &#x0003c;50</td><td>1.90 (1.06, 3.43)</td><td>0.0319</td><td>1.93 (1.02, 3.65)</td><td>0.0425</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>IHC marker</p><p><sup>b</sup>PR was not included as ER and PR are correlated</p><p><sup>c</sup>Tumors excluded if missing data for either Her2 or ER</p></table-wrap-foot></table-wrap></p><p>A similar association to the full group findings was observed when the analysis was restricted to patients who had received no systemic adjuvant treatment (Log-Rank <italic>P</italic>&#x02009;=&#x02009;0.0353, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). When Mena<sup>calc</sup> status was considered alone, there was a 2.14-fold (CI&#x02009;=&#x02009;(1.05, 4.58), <italic>P</italic>&#x02009;=&#x02009;0.0445) higher risk of death in the Mena<sup>calc</sup> high group (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The magnitude and the significance of the association of high Mena<sup>calc</sup> with death persisted with adjustment for the same variables as for the full group (HR&#x02009;=&#x02009;3.80, CI&#x02009;=&#x02009;(1.58, 9.97), <italic>P</italic>&#x02009;=&#x02009;0.0052) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). An association was not detected in the treated group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), but a test comparing the Mena<sup>calc</sup> association in the treated versus the untreated group (MV HR&#x02009;=&#x02009;1.38 versus HR&#x02009;=&#x02009;3.37) was equivocal due to low power to detect interaction (ratio of treated versus untreated MV HRs&#x02009;=&#x02009;0.41, CI&#x02009;=&#x02009;(0.12, 1.32), <italic>P</italic>&#x02009;=&#x02009;0.1500) (data not shown).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Results of Overall Survival Analysis by Cox Proportional Hazards Model for the untreated subgroup</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Prognostic Factor</th><th colspan="2">Univariate (<italic>n</italic>&#x02009;=&#x02009;142)</th><th colspan="2">Multivariate (<italic>n</italic>&#x02009;=&#x02009;129<sup>c</sup>)</th></tr></thead><tbody><tr><td colspan="2"/><td>HR (95&#x000a0;% CI)</td><td><italic>P</italic>-value</td><td>HR (95&#x000a0;% CI)</td><td><italic>P</italic>-value</td></tr><tr><td colspan="6">Mena<sup>calc</sup></td></tr><tr><td/><td>High vs. Low</td><td>2.14 (1.05, 4.58)</td><td>0.0445</td><td>3.80 (1.58, 9.97)</td><td>0.0052</td></tr><tr><td colspan="6">Her2<sup>a</sup></td></tr><tr><td/><td>Positive vs. Negative</td><td>1.59 (0.43, 4.31)</td><td>0.4234</td><td>1.35 (0.34, 4.02)</td><td>0.6376</td></tr><tr><td colspan="6">Tumor Size</td></tr><tr><td/><td>&#x02265;2&#x000a0;cm vs. &#x0003c;2&#x000a0;cm</td><td>2.05 (1.01, 4.22)</td><td>0.0508</td><td>1.41 (0.62, 3.23)</td><td>0.4178</td></tr><tr><td colspan="6">ER<sup>a</sup></td></tr><tr><td/><td>Negative vs. Positive</td><td>1.62 (0.68, 3.51)</td><td>0.2504</td><td>0.99 (0.36, 2.51)</td><td>0.9863</td></tr><tr><td colspan="6">PR*</td></tr><tr><td/><td>Positive vs. Negative</td><td>2.84 (1.27, 7.05)</td><td>0.0173</td><td>NA<sup>b</sup></td><td>NA<sup>b</sup></td></tr><tr><td colspan="6">Histological grade</td></tr><tr><td/><td>Grade 2-3 vs. Grade 1</td><td>2.61 (1.09, 7.43)</td><td>0.0505</td><td>1.85 (0.67, 5.84)</td><td>0.2719</td></tr><tr><td/><td>ND vs. Grade 1</td><td>1.46 (0.39, 5.23)</td><td>0.5667</td><td>1.34 (0.33, 5.03)</td><td>0.6763</td></tr><tr><td colspan="6">Lymphatic invasion</td></tr><tr><td/><td>Present vs. Absent</td><td>2.11 (0.81, 4.75)</td><td>0.0993</td><td>1.63 (0.54, 4.16)</td><td>0.3537</td></tr><tr><td colspan="6">Age, years</td></tr><tr><td/><td>&#x02265;50 vs. &#x0003c;50</td><td>2.41 (1.03, 6.77)</td><td>0.0666</td><td>3.03 (1.17, 9.11)</td><td>0.0348</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>IHC marker</p><p><sup>b</sup>PR was not included as ER and PR are correlated</p><p><sup>c</sup>Tumors excluded if missing data for either Her2 or ER</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Molecular subtypes (n&#x02009;=&#x02009;233)</title><p>When the tumors were subdivided into immunohistochemical subtypes, 8.5&#x000a0;% were classified as HER2, 20.5&#x000a0;% were classified as basal, and 70.5&#x000a0;% were classified as luminal. Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows K-M survival curves for the association between the Mena<sup>calc</sup> status (high vs. low) and survival in the three main subtype groups: HER2 (n&#x02009;=&#x02009;20), basal (n&#x02009;=&#x02009;48) and luminal (n&#x02009;=&#x02009;165). Although the subtype tests of association did not attain nominal 5&#x000a0;% significance, the plots show the same trend of high Mena<sup>calc</sup> association with worse survival.<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier analysis of Mena<sup>calc</sup> for ANN tumors subclassified by immunohistochemical subtype: HER2 amplified (n&#x02009;=&#x02009;20, top left), basal (n&#x02009;=&#x02009;48, top right) and luminal (n&#x02009;=&#x02009;165, bottom left). In brackets is the total number of patients followed by the number of patient deaths for each group</p></caption><graphic xlink:href="12885_2015_1468_Fig2_HTML" id="d30e3047"/></fig></p></sec></sec></sec><sec id="Sec16" sec-type="conclusion"><title>Conclusions</title><p>The findings of this study suggest that Mena<sup>calc</sup> is prognostic for ANN breast cancer. While high Mena<sup>calc</sup> values were correlated with poor prognostic features (i.e., high tumor grade, lymphatic invasion), they were also associated with decreased overall survival in our cohort of 403 ANN breast cancer patients, independent of standard prognostic variables. These results complement our previous findings in two independent cohorts of breast cancer patients which indicated that relatively high Mena<sup>calc</sup> values were associated with increased risk of death from breast cancer [<xref ref-type="bibr" rid="CR29">29</xref>]. However, in the previous study, where the number of ANN patients was considerably less than in the present study, Mena<sup>calc</sup> was not associated with risk of death from breast cancer in the ANN subgroup.</p><p>While Mena<sup>calc</sup> may have clinical utility, there were two main limitations which may impact interpretation of our results. First of all, due to limited tumor material, the cohort was skewed to consist primarily of young women with larger tumors and a luminal immunohistochemical profile. Although Mena<sup>calc</sup> may be able to subdivide these patients into low and high risk of recurrence groups, these patients are already considered to be at high risk of negative outcome and are usually managed aggressively. Second of all, this study did not have a validation cohort which would have helped to better assess the prognostic capabilities of Mena<sup>calc</sup>.</p><p>Mena<sup>calc</sup> has been shown to be an independent negative prognostic marker in three breast cancer patient cohorts, including this ANN cohort. Taken together, these findings strongly suggest that Mena<sup>calc</sup> should be investigated further as a potential clinical tool. Future studies could explore the predictive capabilities of Mena<sup>calc</sup> in older ANN patients with a lower risk of recurrence (i.e., smaller tumor size). Also, investigating the prognostic value of Mena<sup>calc</sup> in a cohort with larger proportions of the other molecular subtypes (i.e., basal, HER2) may uncover an association with specific biological/ clinical behavior. Finally, while findings on TMA specimens are promising, future work could compare the performance of Mena<sup>calc</sup> on TMAs to that seen on whole slide specimens as a step towards use in clinical practice.</p></sec></body><back><app-group><app id="App1"><sec id="Sec17"><title>Additional file</title><p>
<media position="anchor" xlink:href="12885_2015_1468_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Time to disease recurrence for the sites of metastasis in the ANN cohort.</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ANN</term><def><p>Axillary node-negative</p></def></def-item><def-item><term>AQUA</term><def><p>Automated quantitative analysis</p></def></def-item><def-item><term>CK5</term><def><p>Cytokeratin 5</p></def></def-item><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>EGF</term><def><p>Epidermal growth factor</p></def></def-item><def-item><term>EGFR</term><def><p>Epidermal growth factor receptor</p></def></def-item><def-item><term>Ena</term><def><p>Enabled</p></def></def-item><def-item><term>ER</term><def><p>Estrogen receptor</p></def></def-item><def-item><term>HER2</term><def><p>Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>HR</term><def><p>Hazard ratio</p></def></def-item><def-item><term>IHC</term><def><p>Immunohistochemical</p></def></def-item><def-item><term>K-M</term><def><p>Kaplan Meier</p></def></def-item><def-item><term>LVI</term><def><p>Lymphatic invasion</p></def></def-item><def-item><term>MV</term><def><p>Multivariate</p></def></def-item><def-item><term>OS</term><def><p>Overall survival</p></def></def-item><def-item><term>PH</term><def><p>Proportional hazards</p></def></def-item><def-item><term>PgR</term><def><p>Progesterone receptor</p></def></def-item><def-item><term>RT-PCR</term><def><p>Real-time polymerase chain reaction</p></def></def-item><def-item><term>TMA</term><def><p>Tissue microarray</p></def></def-item><def-item><term>TMEM</term><def><p>Tumor microenvironment of metastasis</p></def></def-item><def-item><term>UV</term><def><p>Univariate</p></def></def-item><def-item><term>VASP</term><def><p>Vasodilator-stimulated phosphoprotein</p></def></def-item><def-item><term>VEGF</term><def><p>Vascular endothelial growth factor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>Drs. Forse, Agarwal, Pinnaduwage, Lin, Xue, Johung, Mulligan, Bull and Andrulis have no competing interests to declare. Drs. Gertler, Condeelis and Rohan are consultants and shareholders of Metastat Inc., the company that holds the exclusive license to the Mena patent suite. Dr. Condeelis is a consultant for and receives research support from Deciphera Pharmaceuticals. Dr. Condeelis participates in the Speaker&#x02019;s Bureau for Leica Inc.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>SA, ILA, FG, JSC, and TER were involved in the original study design; SA and KJ performed the immunofluorescence and AQUA validation; CLF, SA, DP, JL and XX were involved in data collection and analysis; DP and SBB performed the statistical analysis; AMM performed the pathology review; CLF, DP, SBB, ILA, JSC and TER were involved in manuscript preparation. All of the authors contributed to the final version of the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><p>This research was supported in part by a grant from the Canadian Institutes of Health Research (ILA, SBB), Syd Cooper Program for the Prevention of Cancer Progression (ILA), GM8801 and NCI CA112967 (FBG), and CA100324 (TER, JSC).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaz-Luis</surname><given-names>I</given-names></name><name><surname>Ottesen</surname><given-names>RA</given-names></name><name><surname>Hughes</surname><given-names>ME</given-names></name><name><surname>Mamet</surname><given-names>R</given-names></name><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Edge</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><issue>20</issue><fpage>2142</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.53.1608</pub-id><?supplied-pmid 24888816?><pub-id pub-id-type="pmid">24888816</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Capra</surname><given-names>AM</given-names></name><name><surname>Quesenberry</surname><given-names>CP</given-names><suffix>Jr</suffix></name><name><surname>Fulton</surname><given-names>R</given-names></name><name><surname>Shiraz</surname><given-names>P</given-names></name><name><surname>Habel</surname><given-names>LA</given-names></name></person-group><article-title>Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><issue>20</issue><fpage>2151</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.52.0858</pub-id><?supplied-pmid 24888815?><pub-id pub-id-type="pmid">24888815</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Litton</surname><given-names>JK</given-names></name><name><surname>Broglio</surname><given-names>KR</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Rakkhit</surname><given-names>R</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><etal/></person-group><article-title>High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1&#x000a0;cm or smaller</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>34</issue><fpage>5700</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.2025</pub-id><?supplied-pmid 19884543?><pub-id pub-id-type="pmid">19884543</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><issue>19</issue><fpage>10869</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id><?supplied-pmid 11553815?><pub-id pub-id-type="pmid">11553815</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veer LJ</surname><given-names>V 't</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title><source>Nature</source><year>2002</year><volume>415</volume><issue>6871</issue><fpage>530</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/415530a</pub-id><pub-id pub-id-type="pmid">11823860</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blows</surname><given-names>FM</given-names></name><name><surname>Driver</surname><given-names>KE</given-names></name><name><surname>Schmidt</surname><given-names>MK</given-names></name><name><surname>Broeks</surname><given-names>A</given-names></name><name><surname>van Leeuwen</surname><given-names>FE</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><etal/></person-group><article-title>Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies</article-title><source>PLoS Med</source><year>2010</year><volume>7</volume><issue>5</issue><pub-id pub-id-type="doi">10.1371/journal.pmed.1000279</pub-id><?supplied-pmid 20520800?><pub-id pub-id-type="pmid">20520800</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gertler</surname><given-names>FB</given-names></name><name><surname>Niebuhr</surname><given-names>K</given-names></name><name><surname>Reinhard</surname><given-names>M</given-names></name><name><surname>Wehland</surname><given-names>J</given-names></name><name><surname>Soriano</surname><given-names>P</given-names></name></person-group><article-title>Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics</article-title><source>Cell</source><year>1996</year><volume>87</volume><issue>2</issue><fpage>227</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81341-0</pub-id><?supplied-pmid 8861907?><pub-id pub-id-type="pmid">8861907</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barzik</surname><given-names>M</given-names></name><name><surname>Kotova</surname><given-names>TI</given-names></name><name><surname>Higgs</surname><given-names>HN</given-names></name><name><surname>Hazelwood</surname><given-names>L</given-names></name><name><surname>Hanein</surname><given-names>D</given-names></name><name><surname>Gertler</surname><given-names>FB</given-names></name><etal/></person-group><article-title>Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>31</issue><fpage>28653</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1074/jbc.M503957200</pub-id><?supplied-pmid 15939738?><pub-id pub-id-type="pmid">15939738</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Modugno</surname><given-names>F</given-names></name><name><surname>Bronzi</surname><given-names>G</given-names></name><name><surname>Scanlan</surname><given-names>MJ</given-names></name><name><surname>Del Bello</surname><given-names>D</given-names></name><name><surname>Cascioli</surname><given-names>S</given-names></name><name><surname>Venturo</surname><given-names>I</given-names></name><etal/></person-group><article-title>Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response</article-title><source>Int J Cancer</source><year>2004</year><volume>109</volume><issue>6</issue><fpage>909</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/ijc.20094</pub-id><?supplied-pmid 15027125?><pub-id pub-id-type="pmid">15027125</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Modugno</surname><given-names>F</given-names></name><name><surname>Mottolese</surname><given-names>M</given-names></name><name><surname>Di Benedetto</surname><given-names>A</given-names></name><name><surname>Conidi</surname><given-names>A</given-names></name><name><surname>Novelli</surname><given-names>F</given-names></name><name><surname>Perracchio</surname><given-names>L</given-names></name><etal/></person-group><article-title>The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><issue>5</issue><fpage>1470</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2027</pub-id><?supplied-pmid 16533770?><pub-id pub-id-type="pmid">16533770</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Philippar</surname><given-names>U</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Patsialou</surname><given-names>A</given-names></name><name><surname>Avraham</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo</article-title><source>Clin Exp Metastasis</source><year>2009</year><volume>26</volume><issue>2</issue><fpage>153</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s10585-008-9225-8</pub-id><?supplied-pmid 18985426?><pub-id pub-id-type="pmid">18985426</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gertler</surname><given-names>F</given-names></name><name><surname>Condeelis</surname><given-names>J</given-names></name></person-group><article-title>Metastasis: tumor cells becoming MENAcing</article-title><source>Trends Cell Biol</source><year>2011</year><volume>21</volume><issue>2</issue><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2010.10.001</pub-id><?supplied-pmid 21071226?><pub-id pub-id-type="pmid">21071226</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Lapidus</surname><given-names>K</given-names></name><name><surname>Wells</surname><given-names>AL</given-names></name><name><surname>Wyckoff</surname><given-names>JB</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name><etal/></person-group><article-title>Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>23</issue><fpage>8585</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1136</pub-id><?supplied-pmid 15574765?><pub-id pub-id-type="pmid">15574765</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wyckoff</surname><given-names>JB</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sidani</surname><given-names>M</given-names></name><name><surname>Segall</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>8</issue><fpage>3505</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3714</pub-id><?supplied-pmid 17440055?><pub-id pub-id-type="pmid">17440055</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patsialou</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Whitney</surname><given-names>K</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Kenny</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients</article-title><source>Breast Cancer Res</source><year>2012</year><volume>14</volume><issue>5</issue><fpage>R139</fpage><pub-id pub-id-type="doi">10.1186/bcr3344</pub-id><?supplied-pmid 23113900?><pub-id pub-id-type="pmid">23113900</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patsialou</surname><given-names>A</given-names></name><name><surname>Bravo-Cordero</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Entenberg</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors</article-title><source>Intravital</source><year>2013</year><volume>2</volume><issue>2</issue><pub-id pub-id-type="doi">10.4161/intv.25294</pub-id><?supplied-pmid 25013744?><pub-id pub-id-type="pmid">25013744</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philippar</surname><given-names>U</given-names></name><name><surname>Roussos</surname><given-names>ET</given-names></name><name><surname>Oser</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>HD</given-names></name><name><surname>Giampieri</surname><given-names>S</given-names></name><etal/></person-group><article-title>A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis</article-title><source>Dev Cell</source><year>2008</year><volume>15</volume><issue>6</issue><fpage>813</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2008.09.003</pub-id><?supplied-pmid 19081071?><pub-id pub-id-type="pmid">19081071</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>ET</given-names></name><name><surname>Balsamo</surname><given-names>M</given-names></name><name><surname>Alford</surname><given-names>SK</given-names></name><name><surname>Wyckoff</surname><given-names>JB</given-names></name><name><surname>Gligorijevic</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer</article-title><source>J Cell Sci</source><year>2011</year><volume>124</volume><issue>Pt 13</issue><fpage>2120</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1242/jcs.086231</pub-id><?supplied-pmid 21670198?><pub-id pub-id-type="pmid">21670198</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>ET</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Balsamo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Stobezki</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>E</given-names></name><etal/></person-group><article-title>Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM</article-title><source>Clin Exp Metastasis</source><year>2011</year><volume>28</volume><issue>6</issue><fpage>515</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s10585-011-9388-6</pub-id><?supplied-pmid 21484349?><pub-id pub-id-type="pmid">21484349</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>ET</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wyckoff</surname><given-names>JB</given-names></name><name><surname>Sellers</surname><given-names>RS</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors</article-title><source>Breast Cancer Res</source><year>2010</year><volume>12</volume><issue>6</issue><fpage>R101</fpage><pub-id pub-id-type="doi">10.1186/bcr2784</pub-id><?supplied-pmid 21108830?><pub-id pub-id-type="pmid">21108830</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyckoff</surname><given-names>JB</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>EY</given-names></name><name><surname>Li</surname><given-names>JF</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Stanley</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>6</issue><fpage>2649</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1823</pub-id><?supplied-pmid 17363585?><pub-id pub-id-type="pmid">17363585</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian B-Z et al. Real-time imaging of the tumor microenvironment reveals local, transient vascular permeability and tumor cell intravasation stimulated by macrophage-derived VEGF. Cancer Discovery. 2015; in press.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyckoff</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>EY</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pixley</surname><given-names>F</given-names></name><name><surname>Stanley</surname><given-names>ER</given-names></name><etal/></person-group><article-title>A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>19</issue><fpage>7022</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1449</pub-id><?supplied-pmid 15466195?><pub-id pub-id-type="pmid">15466195</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>ET</given-names></name><name><surname>Condeelis</surname><given-names>JS</given-names></name><name><surname>Patsialou</surname><given-names>A</given-names></name></person-group><article-title>Chemotaxis in cancer</article-title><source>Nat Rev Cancer</source><year>2011</year><volume>11</volume><issue>8</issue><fpage>573</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1038/nrc3078</pub-id><?supplied-pmid 21779009?><pub-id pub-id-type="pmid">21779009</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>IM</given-names></name><name><surname>Cheng</surname><given-names>AW</given-names></name><name><surname>Flytzanis</surname><given-names>NC</given-names></name><name><surname>Balsamo</surname><given-names>M</given-names></name><name><surname>Condeelis</surname><given-names>JS</given-names></name><name><surname>Oktay</surname><given-names>MH</given-names></name><etal/></person-group><article-title>An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype</article-title><source>PLoS Gen</source><year>2011</year><volume>7</volume><issue>8</issue><pub-id pub-id-type="doi">10.1371/journal.pgen.1002218</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pignatelli</surname><given-names>J</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>JG</given-names></name><name><surname>Rohan</surname><given-names>TE</given-names></name><name><surname>Pieri</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration</article-title><source>Sci Signal</source><year>2014</year><volume>7</volume><issue>353</issue><fpage>ra112</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2005329</pub-id><?supplied-pmid 25429076?><pub-id pub-id-type="pmid">25429076</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>BD</given-names></name><name><surname>Sica</surname><given-names>GL</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Rohan</surname><given-names>TE</given-names></name><name><surname>Gertler</surname><given-names>FB</given-names></name><name><surname>Condeelis</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><issue>7</issue><fpage>2433</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2179</pub-id><?supplied-pmid 19318480?><pub-id pub-id-type="pmid">19318480</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Rohan TE, Xue X, Lin HM, D'Alfonso TM, Ginter PS, Oktay MH et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst. 2014;106(8). doi:10.1093/jnci/dju136.</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Gertler</surname><given-names>FB</given-names></name><name><surname>Balsamo</surname><given-names>M</given-names></name><name><surname>Condeelis</surname><given-names>JS</given-names></name><name><surname>Camp</surname><given-names>RL</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><etal/></person-group><article-title>Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer</article-title><source>Breast Cancer Res</source><year>2012</year><volume>14</volume><issue>5</issue><fpage>R124</fpage><pub-id pub-id-type="doi">10.1186/bcr3318</pub-id><?supplied-pmid 22971274?><pub-id pub-id-type="pmid">22971274</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bull</surname><given-names>SB</given-names></name><name><surname>Ozcelik</surname><given-names>H</given-names></name><name><surname>Pinnaduwage</surname><given-names>D</given-names></name><name><surname>Blackstein</surname><given-names>ME</given-names></name><name><surname>Sutherland</surname><given-names>DA</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><etal/></person-group><article-title>The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>1</issue><fpage>86</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.09.128</pub-id><?supplied-pmid 14701769?><pub-id pub-id-type="pmid">14701769</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrulis</surname><given-names>IL</given-names></name><name><surname>Bull</surname><given-names>SB</given-names></name><name><surname>Blackstein</surname><given-names>ME</given-names></name><name><surname>Sutherland</surname><given-names>D</given-names></name><name><surname>Mak</surname><given-names>C</given-names></name><name><surname>Sidlofsky</surname><given-names>S</given-names></name><etal/></person-group><article-title>neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><issue>4</issue><fpage>1340</fpage><lpage>9</lpage><?supplied-pmid 9552035?><pub-id pub-id-type="pmid">9552035</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name><name><surname>Taube</surname><given-names>SE</given-names></name><name><surname>Gion</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name></person-group><article-title>REporting recommendations for tumour MARKer prognostic studies (REMARK)</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><issue>4</issue><fpage>387</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6602678</pub-id><?supplied-pmid 16106245?><pub-id pub-id-type="pmid">16106245</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>AW</given-names></name><name><surname>Moeder</surname><given-names>CB</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Gershkovich</surname><given-names>P</given-names></name><name><surname>Alarid</surname><given-names>ET</given-names></name><name><surname>Harigopal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>22</issue><fpage>2978</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.32.9706</pub-id><?supplied-pmid 21709197?><pub-id pub-id-type="pmid">21709197</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camp</surname><given-names>RL</given-names></name><name><surname>Chung</surname><given-names>GG</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name></person-group><article-title>Automated subcellular localization and quantification of protein expression in tissue microarrays</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><issue>11</issue><fpage>1323</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nm791</pub-id><?supplied-pmid 12389040?><pub-id pub-id-type="pmid">12389040</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moeder</surname><given-names>CB</given-names></name><name><surname>Giltnane</surname><given-names>JM</given-names></name><name><surname>Moulis</surname><given-names>SP</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name></person-group><article-title>Quantitative, fluorescence-based in-situ assessment of protein expression</article-title><source>Methods Mol Biol.</source><year>2009</year><volume>520</volume><fpage>163</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/978-1-60327-811-9_12</pub-id><?supplied-pmid 19381954?><pub-id pub-id-type="pmid">19381954</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornegoor</surname><given-names>R</given-names></name><name><surname>Verschuur-Maes</surname><given-names>AH</given-names></name><name><surname>Buerger</surname><given-names>H</given-names></name><name><surname>Hogenes</surname><given-names>MC</given-names></name><name><surname>de Bruin</surname><given-names>PC</given-names></name><name><surname>Oudejans</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Molecular subtyping of male breast cancer by immunohistochemistry</article-title><source>Mod Pathol</source><year>2012</year><volume>25</volume><issue>3</issue><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2011.174</pub-id><?supplied-pmid 22056953?><pub-id pub-id-type="pmid">22056953</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livasy</surname><given-names>CA</given-names></name><name><surname>Karaca</surname><given-names>G</given-names></name><name><surname>Nanda</surname><given-names>R</given-names></name><name><surname>Tretiakova</surname><given-names>MS</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Moore</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma</article-title><source>Mod Pathol</source><year>2006</year><volume>19</volume><issue>2</issue><fpage>264</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3800528</pub-id><?supplied-pmid 16341146?><pub-id pub-id-type="pmid">16341146</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voduc</surname><given-names>KD</given-names></name><name><surname>Cheang</surname><given-names>MC</given-names></name><name><surname>Tyldesley</surname><given-names>S</given-names></name><name><surname>Gelmon</surname><given-names>K</given-names></name><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Kennecke</surname><given-names>H</given-names></name></person-group><article-title>Breast cancer subtypes and the risk of local and regional relapse</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>10</issue><fpage>1684</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.24.9284</pub-id><?supplied-pmid 20194857?><pub-id pub-id-type="pmid">20194857</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinze</surname><given-names>G</given-names></name><name><surname>Schemper</surname><given-names>M</given-names></name></person-group><article-title>A solution to the problem of monotone likelihood in Cox regression</article-title><source>Biometrics</source><year>2001</year><volume>57</volume><issue>1</issue><fpage>114</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.0006-341X.2001.00114.x</pub-id><?supplied-pmid 11252585?><pub-id pub-id-type="pmid">11252585</pub-id></element-citation></ref></ref-list></back></article>